Video

Sequencing Strategies in BRAF-Mutated mCRC

An in-depth review of the current treatment options and sequencing approaches to BRAF-mutant metastatic colorectal cancer (mCRC) according to the NCCN guidelines.

Related Videos
Kimmie Ng, MD, MPH
Piotr Rutkowski, MD
Yelena Y. Janjigian, MD
Zhi Peng, MD
Josep Llovet, MD
Cathy Eng, MD, FACP, FASCO
Kimmie Ng, MD, MPH
Ruihua Xu, MD, PhD, professor, medical oncology, Department of Medical Oncology, president, Sun Yat-sen University Cancer Center, chairman, Chinese Society of Clinical Oncology
Kimmie Ng, MD, MPH
Thierry Andre, MD, professor, medical oncology, Sorbonne Université; head, Medical Oncology Department, Saint Antoine Hospital
Related Content
Kristen K. Ciombor, MD, MSCI
October 11th 2024

Treatment Personalization Is Poised to Define New Era of mCRC Therapy

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

FDA
October 9th 2024

FDA Grants Orphan Drug Designation to Namodenoson for Pancreatic Cancer

Oncology Unplugged
August 21st 2024

Park and Kasi Expand on Perioperative Immunotherapy Updates in CRC

State of Science Summit: Gastrointestinal Cancer - Chaired by: Tanios Bekaii-Saab, MD and Darshil Shah, MD, MPH
October 2nd 2024

State of Science Summit: Gastrointestinal Cancer - Chaired by: Tanios Bekaii-Saab, MD and Darshil Shah, MD, MPH

Botensilimab/Baltstilimab in MSS CRC | Image Credit: © Dr_Microbe - stock.adobe.com
October 2nd 2024

Neoantigen-Directed GRANITE Immunotherapy Improves PFS as Maintenance in MSS mCRC